<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02850848</url>
  </required_header>
  <id_info>
    <org_study_id>YSP RHH3001-01</org_study_id>
    <nct_id>NCT02850848</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Two Formulations of Entecavir</brief_title>
  <official_title>A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of a Test Formulation of Entigin Film Coated Tablet 0.5mg (Entecavir 0.5 mg), Compared to an Equivalent Dose of a Reference Drug Product (Baraclude 0.5mg Tablets) in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yung Shin Pharm. Ind. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yung Shin Pharm. Ind. Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of a Test
      Formulation of Entigin Film Coated Tablet 0.5mg (Entecavir 0.5 mg), Compared to an Equivalent
      Dose of a Reference Drug Product (Baraclude 0.5mg Tablets) in Healthy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration(AUC)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax(Tmax)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Drug Concentration(Cmax)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life(T1/2)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the (first) moment plasma concentration-time curve(AUMC)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time(MRT)</measure>
    <time_frame>Plasma sample: 0, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 84, 132 and 168 hr Urine sample: -2~0, 0~6, 6~12, 12~24, 24~36, 36~48 hr</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>The safety was monitored throughout the study. Up to 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Entigin Film Coated Tablet 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entigin Film Coated Tablet 0.5mg Dosing Regimen: Single dosing of two tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baraclude 0.5mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baraclude 0.5mg Tablets Dosing Regimen: Single dosing of two tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entigin Film Coated Tablet 0.5mg</intervention_name>
    <arm_group_label>Entigin Film Coated Tablet 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Baraclude 0.5mg Tablets</intervention_name>
    <arm_group_label>Baraclude 0.5mg Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult, aged between 20 to 45 years old.

          2. Physically and mentally healthy subjects as confirmed by an interview, medical
             history, clinical examination, laboratory tests, chest x-ray and electrocardiogram.

               -  no particular clinical significance in clinical examination and laboratory tests
                  within two months (60 days) prior to administration of study medication.

               -  normal or considered not clinically significant by the investigator chest X-ray
                  and Electrocardiogram (ECG) results within six months(180 days)prior to
                  administration of study medication.

          3. Body weight must be above 50 kg for male and 45 kg for female.

          4. The normal range of the body mass index should be between 18 and 30; body mass index
             equals [weight (kg)]/[height (m)]2.

          5. Laboratory determinations results are within normal range or considered not clinically
             significant by the investigator, including: Serum Glutamic Oxaloacetic Transaminase
             (SGOT, same as AST), Serum Glutamic Pyruvic Transaminase (SGPT, same as ALT), albumin,
             glucose, creatinine, uric acid, cholesterol, Triglycerides (TG),
             Gamma-Glutamyl-Transpeptidase (Î³-GT), alkaline phosphatase, total bilirubin, Blood
             Urea Nitrogen (BUN), Hepatitis B surface antigen (HBsAg), Anti-Hepatitis C virus (HCV)
             and Anti-Human Immunodeficiency Virus (HIV) test.

          6. Hematology test results are within normal range or considered not clinically
             significant by the investigator, including: hemoglobin, hematocrit, White Blood Cell
             (WBC) count, Red Blood Cell (RBC) count, platelet count and WBC count with
             differential.

          7. Urinalysis results are within normal range or considered not clinically significant by
             the investigator, including: glucose, protein, RBC, WBC, epithelial cells, casts and
             bacteria.

          8. Female subject who is:

               -  using adequate contraception since last menstruation and no plan for conception
                  during the study.

               -  non-lactating.

               -  has negative pregnancy test (urine) prior to the study.

          9. Informed consent form signed.

        Exclusion Criteria:

          1. A history of drug or alcohol abuse during the past 24 weeks.

          2. Sensitivity to analogous drug.

          3. A clinically significant illness (such as lactic acidosis or severe hepatomegaly with
             steatosis) within the past 4 weeks.

          4. Evidence of any clinical significant renal, cardiovascular, hepatic, hematopoietic,
             neurological, pulmonary or gastrointestinal pathology within the past 4 weeks.

          5. Planned vaccination during the time course of the study.

          6. Participation of any clinical investigation during the last 60 days.

          7. Regular use of any medication during the last 4 weeks.

          8. Single use of any medication during the last 2 weeks.

          9. Blood donation of more than 250 mL within the past 12 weeks.

         10. Employees and their families of sponsor and/or Contract Research Organization (CRO)
             company.

         11. Individuals are judged by the investigator or co-investigator to be undesirable as
             subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2016</study_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

